Saturday 17 October 2026
Export TRIB’s income statement to Excel — free account
Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
8.03
0.10
+1.26%
Follow TRIB
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 55.26% | 69.76% | 90.93% | 92.42% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 4 | 2 | 1 | |
| (32.70%) | (35.86%) | (36.64%) | (37.61%) | ||
ROIC |
(12.61%) | (16.99%) | (23.73%) | (25.55%) | |
Return on Tangible Assets |
30.75% | 37.37% | (732.37%) | (630.54%) | |
Average Days of Receivables |
81.54 | 95.70 | 108.88 | 80.47 | |
Free Cash Flow per Share |
(6.78) | (22.76) | (18.00) | (26.07) | |
Free Cash Flow |
(4.28) | (14.08) | (11.18) | (16.17) | |
Capital Expenditures |
(0.07) | (8.15) | (10.08) | (11.31) | |
| Other line items | |||||
Cash ROIC |
(6.76%) | (20.60%) | (18.19%) | (26.06%) | |
Accounts Receivable Turnover |
4.46 | 3.18 | 2.72 | 3.48 | |
Accounts Payable Turnover |
1.02 | 0.95 | 1.10 | 1.32 | |
Inventory Turnover |
1.47 | 1.41 | 1.50 | 1.52 | |
Average Days of Payables |
385.95 | 403.06 | 360.86 | 295.61 | |
Days of Inventory on Hand |
236.11 | 255.49 | 227.75 | 224.66 | |
Tax Rate |
0.01 | 0.01 | 0.03 | 0.02 | |
Research and Development Expense of Revenue |
7.29% | 8.29% | 8.28% | 8.53% | |
Selling, General and Administrative Expense of Revenue |
57.87% | 66.06% | 64.01% | 63.72% | |
Share Based Compensation of Revenue |
0.44% | 0.74% | 0.88% | 1.24% | |
Interest Coverage |
(0.57) | (0.74) | (1.85) | (2.21) | |
Operating CF/Net income |
0.13 | 0.16 | 0.03 | 0.13 | |
Depreciation/Fixed assets |
0.54 | 0.51 | 0.59 | 0.54 | |
Capex/Depreciation |
(0.03) | (3.04) | (4.24) | (4.88) | |
Revenue per Share |
74.56 | 70.78 | 78.19 | 79.64 | |
Operating CF per Share |
(6.67) | (9.58) | (1.78) | (7.84) | |
Capex per Share |
(0.12) | (13.17) | (16.23) | (18.23) | |
Capex to Sales |
0.00 | 0.19 | 0.21 | 0.23 |
Columns are period end dates